Over the past decade, lung cancer treatment has undergone a major paradigm shift. A
greater understanding of lung cancer biology has led to the development of many effective …

Immune checkpoint inhibitors are considered standard second-line treatment in advanced
non-small cell lung cancer patients. This strategy has also become standard in first-line …

Lung cancer is one of the most common cancers and the leading cause of cancer-related
deaths worldwide. Most of these patients with non-small cell lung cancer (NSCLC) present …

Background Therapeutic strategies with immune checkpoint inhibitors (ICIs) counteract the
immunosuppressive effects of programmed cell death protein-1 (PD-1) and ligand-1 (PD …

Immune checkpoint inhibitors (ICIs) are new therapeutic strategies for non-small cell lung
cancer (NSCLC). We aimed to quantitatively evaluate the efficacy and safety of ICIs in …

Simple Summary Immunotherapy stands as a cornerstone in the treatment of advanced lung
cancer patients without an oncogenic driver mutation. This comprehensive review provides …

Lung cancer is still a leading cause of cancer death worldwide, with 271 800 predicted
deaths for the year 2014 in the European Union [1]. More than 70% of nonsmall cell lung …

Despite the availability of radiotherapy, cytotoxic agents, and targeted agents, a high unmet
medical need remains for novel therapies that improve treatment outcomes in patients with …

Many decades in the making, immunotherapy has demonstrated its ability to produce
durable responses in several cancer types. In the last decade, immunotherapy has shown …

Immune checkpoint inhibition with blocking antibodies that target cytotoxic T-lymphocyte
antigen-4 (CTLA-4) and the programmed cell death protein 1 (PD-1) pathway [PD …